Table 5 Summary of subgroup analyses: MWA vs. HR
Subgroup | LTR [RR (95% CI); P value; studies (N); I2] | OS (1-year) [RR (95% CI); P value; studies (N); I2] | Complications [RR (95% CI); P value; studies (N); I2] |
|---|---|---|---|
Tumor size | |||
< 3 cm | 2.93 (1.26, 6.81); P = 0.013; 4; 64% | 1.01 (0.99, 1.04); P = 0.41; 3; 0% | 0.57 (0.06, 5.05); P = 0.615; 3; 67% |
≥ 3 cm | 1.24 (0.53, 2.88); P = 0.624; 2; 62% | 0.96 (0.88, 1.04); P = 0.329; 3; 0% | 0.30 (0.14, 0.64); P = 0.002; 2; 0% |
Type of tumor | |||
HCC | 3.04 (1.84, 5.02); P < 0.001; 7; 32% | 1.01 (0.99, 1.03); P = 0.311; 7; 0% | 0.36 (0.19, 0.66); P = 0.001; 6; 21% |
Liver metastases | Too few studies (< 2) to inform | 0.96 (0.88, 1.06); P = 0.451; 3; 0% | 0.22 (0.09, 0.56); P = 0.001; 2; 0% |
MWA frequency | |||
2450 MHz | 2.35 (1.49, 3.70); P < 0.001; 6; 0% | 1.00 (0.98, 1.03); P = 0.766; 8; 0% | 0.35 (0.18, 0.68); P = 0.002; 6; 31% |
915 MHz | 2.44 (0.31, 19.10); P = 0.396; 2; 96% | 0.98 (0.84, 1.14); P = 0.77; 2; 83% | 0.24 (0.10, 0.61); P = 0.002; 2; 0% |